Study of an Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stone Disease (STONES)

This is a single arm, multi-center study to assess the safety and efficacy of a form of extracorporeally induced lithotripsy, called the Enhanced Lithotripsy System, to treat urinary stones.

Study Overview

• Status: Terminated
• Conditions: Urinary Stone
• Intervention / Treatment: Device: Enhanced Lithotripsy System

Detailed Description

This is a single arm, multi-center study to assess the safety and efficacy of a form of extracorporeally induced lithotripsy, called the Enhanced Lithotripsy System, to treat urinary stones. Subjects will be treated up to 2 times with the Enhanced Lithotripsy System and followed for 90 days after the last treatment session.

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Australia
  • New Southwales
    • Campbelltown, New Southwales, Australia, 2560
      • Macarthur Urology
    • Westmead, New Southwales, Australia, 2145
      • Alpha West Mead Private Hospital PTY Limited
  • Victoria
    • Bendigo, Victoria, Australia, 3550
      • Goldfields Urology
    • Heidelberg, Victoria, Australia, 3084
      • Austin Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female aged ≥ 18 years
2. Provides written informed consent
3. Understands and accepts the study requirements

4. One urinary stone eligible for treatment (minimum) that is:

   1. apparent on a computed tomography (CT) scan within 14 days prior to study enrollment
   2. located within the renal pelvis or ureter
   3. is ≥ 3 mm in at least one dimension and ≤ 10 mm in maximum
   4. less than or equal to 10mm in maximum dimension and has an area less than 56mm2 as estimated by pre-procedure CT dimension as estimated by pre- procedure CT

5. Participants with two or more stones in one or both kidneys are admissible and must meet the following inclusion criteria:

   1. Number of stones (≥ 3 mm) present on treated side is 2 or less
   2. Untreated stones must not be anticipated to require treatment within 30 days of enrollment, as determined by the investigator

Exclusion Criteria:

1. Age less than 18 years of age or over 75 years of age
2. Diagnosis of radiolucent stones
3. History of cystinuria
4. Urine pH below 5.5
5. Current untreated urinary tract infection
6. Pregnancy
7. Vulnerable individuals (mentally disabled, physically disabled, prisoner, etc.)
8. Enrollment in another research study or previous participation within 30 days of enrollment.
9. Participant has planned general anesthesia during index procedure with American Society of Anesthesiologists (ASA) physical classification level of 3 or greater
10. Known sensitivity to possible medications used before, during, or after the ELS procedure, including but not limited to the following: sedative agents, general anaesthetics, topical anaesthetics, and opioid analgesics
11. Coagulation abnormality or taking prescription anticoagulants that cannot be stopped during treatment. Aspirin usage will be discontinued at least 7 days prior to enrollment at the discretion of the attending physician
12. Mobility issues - unable to comfortably lie still for up to 120 minutes or unable to roll from back to side
13. Known hypersensitivity to conductivity gel
14. Body mass index (BMI) ≥ 35 unless anticipated skin to stone distance (anticipated distance from site of ELS treatment head to stone per pre-operative CT) is <135mm
15. Implanted spinal cord neurostimulator intrathecal pump or any device that may interfere with energy transmission
16. Participant has open wounds, lesions, dermatitis, or ischemic tissues in the treatment area
17. Participant has had a major surgery that removed tissue around the spinal cord (e.g. a laminectomy) within the treatment area
18. Participant will undergo treatment of a stone located in the distal ureter and has previous hernia repair or surgical mesh implanted in the inguinal/hypogastric regions

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Device Feasibility
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Enhanced Lithotripsy System; Treatment of urinary stone disease with the Enhanced Lithotripsy System	Device: Enhanced Lithotripsy System; Treatment of urinary stone disease with the Enhanced Lithotripsy System

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Treatment Success	Proportion of study participants who, after up to 2 ELS treatments, have a complete absence of stones or with any residual fragments measuring less than 3 mm in the largest dimension as assessed by follow-up imaging	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Serious Device and/or Serious Procedure-Related Adverse Events (Safety)	Incidence of Serious Device and/or Serious Procedure-Related adverse events	30 days

Collaborators and Investigators

• Sponsor: Avvio Medical

Study record dates

Study Major Dates

• Study Start (Actual): February 8, 2019
• Primary Completion (Actual): March 18, 2020
• Study Completion (Actual): October 5, 2022

Study Registration Dates

• First Submitted: February 7, 2019
• First Submitted That Met QC Criteria: February 24, 2021
• First Posted (Actual): February 25, 2021

Study Record Updates

• Last Update Posted (Actual): April 3, 2026
• Last Update Submitted That Met QC Criteria: March 16, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: lithotripsy; urolithiasis; urinary stone
• Additional Relevant MeSH Terms: Urogenital Diseases; Male Urogenital Diseases; Calculi; Pathological Conditions, Anatomical; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Pathological Conditions, Signs and Symptoms; Urinary Calculi; Urolithiasis
• Other Study ID Numbers: 2018-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes